Bioequivalence Study of Revolade® Eltrombopag 50 mg

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions

HealthyHealthy Donors

Interventions

DRUG

Revolade®

Tableta 50 mg Reference

DRUG

Eltrombopag (EPAG)

Tableta 50 mg

Trial Locations (1)

Centro de Atención e Investigación Médica, Chía

All Listed Sponsors

lead

Centro de Atencion e Investigacion Medica

NETWORK

NCT06834451 - Bioequivalence Study of Revolade® Eltrombopag 50 mg | Biotech Hunter | Biotech Hunter